Biogen reports more litifilimab patients had clear or almost clear skin at 52 weeks in cutaneous lupus. Read the latest AMETHYST Phase II results today.

Litfulo Phase III results showed significant repigmentation in nonsegmental vitiligo, supporting planned regulatory filings.

TriGemX Bio raises $94 million to fund Phase III trials of oral migraine drug elismetrep. Discover the investors backing the program and what comes next.

Ubamatamab showed a 73% response rate and 11-month median progression-free survival in 11 LGSOC patients in an early-trial ...

Astrocyte Pharmaceuticals secures $9.5M Series B funding to advance AST-004 into Phase II trials for concussion and TBI ...

Pfizer presented detailed Phase III data for ritlecitinib (Litfulo) in nonsegmental vitiligo (NSV) at the 2026 European Academy of Dermatology and... New York City-based TriGemX Bio (formerly Kallyope ...

Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...

Progentos begins Phase I/II human trial of oral PRO-1562 for multiple sclerosis remyelination. First-in-human study ...

Eli Lilly's retatrutide shows 20.8% weight loss and A1C improvements in type 2 diabetes. TRIUMPH-2 trial results presented at ...

Regeneron and Sanofi expand antibody alliance with $1B upfront and $7B in milestones for IL-4/IL-13 pathway treatments. Learn ...

Atara Biotherapeutics resubmits tabelecleucel BLA to FDA for EBV+ post-transplant lymphoproliferative disease. Latest updates ...

Ortet, a new frontier AI health lab, launches with $500M from Thoreau to build patient-centered foundation models. Learn how ...